Back to News
Nov 28, 2025 12:00 PM

AbbVie Scores Canadian Reimbursement Recommendations For Blockbuster Ulcerative Colitis Drug Skyrizi

On Friday, AbbVie Inc. (NYSE:ABBV) announced two updates for ulcerative colitis patients in Canada.

ABBV is in positive territory. Check the market position here.

Ulcerative colitis is a chronic, immune-mediated inflammatory bowel disease affecting the large intestine, causing persistent inflammation and ulceration of the colon’s lining. Common symptoms include frequent diarrhea, abdominal pain, and rectal bleeding.

Skyrizi (risankizumab), an IL-23 inhibitor, received two consecutive positive reimbursement recommendations by Canada’s Drug Agency for inflammatory bowel diseases, initially for Crohn’s disease and now for ulcerative colitis, supported by evidence from pivotal phase 3 clinical trials including MOTIVATE, ADVANCE, FORTIFY (for Crohn’s disease), and INSPIRE, COMMAND (for ulcerative colitis).

Also Read: